

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role

for nanomaterial substances
NEWS 27 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China
NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:28:31 ON 30 MAR 2009

=> file reg
COST IN U.S. DOLLARS
SINCE FILE ENTRY TOTAL
SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 11:28:43 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2
DICTIONARY FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10553982 updated.str



```
chain nodes :  
6 7 11 12  
ring nodes :  
1 2 3 4 5 9  
chain bonds :  
1-6 3-12 4-11 6-7 6-9  
ring bonds :  
1-2 1-5 2-3 3-4 4-5  
exact/norm bonds :  
1-2 1-5 2-3 3-4 3-12 4-5 4-11 6-7 6-9  
exact bonds :  
1-6  
isolated ring systems :  
containing 1 :
```


G1:O,S

G2:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:Atom 11:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	0.48	0.70	

FILE 'CAPLUS' ENTERED AT 11:29:02 ON 30 MAR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2009 VOL 150 ISS 14
 FILE LAST UPDATED: 29 Mar 2009 (20090329/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11 SSS full
 REGISTRY INITIATED
 Substance data SEARCH and crossover from CAS REGISTRY in progress...
 Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:29:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 234495 TO ITERATE

81.3% PROCESSED 190655 ITERATIONS 462 ANSWERS
100.0% PROCESSED 234495 ITERATIONS 462 ANSWERS
SEARCH TIME: 00.00.21

L2 462 SEA SSS FUL L1

L3 9 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:380879 CAPLUS Full-text
DOCUMENT NUMBER: 144:432814
TITLE: Preparation of 1,5-diheterocyclyl-1H-triazole derivatives as platelet aggregation inhibitors
INVENTOR(S): Kanaya, Naoaki; Fujii, Kunihiko
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006043594	A1	20060427	WO 2005-JP19207	20051019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005296582	A1	20060427	AU 2005-296582	20051019
CA 2583153	A1	20060427	CA 2005-2583153	20051019
EP 1803719	A1	20070704	EP 2005-795875	20051019
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101039934	A	20070919	CN 2005-80035228	20051019
NO 2007001826	A	20070614	NO 2007-1826	20070410
KR 2007063530	A	20070619	KR 2007-708162	20070410
MX 2007004643	A	20070608	MX 2007-4643	20070418
US 20080125409	A1	20080529	US 2007-577476	20070418

PRIORITY APPLN. INFO.:

JP 2004-303851

A 20041019


WO 2005-JP19207

W 20051019

OTHER SOURCE(S):

MARPAT 144:432814

GI



AB The title compds. represented by the general formula (I) [wherein Ar1, Ar2 = (un)substituted 5- or 6-membered aromatic heterocyclyl; R1, R2 = H, each (un)substituted lower alkyl, alicyclic heterocyclyl, carbamoyl, or NH2 HO; or NR1R2 together represents an (un)substituted 4- to 7-membered alicyclic heterocyclyl optionally containing one N or O atom other than the ring N atom], salts thereof, or solvates of either are prepared. These compds. are potent platelet aggregation inhibitors which inhibit neither COX-1 nor COX-2, and are useful for the prevention and treatment of ischemic diseases. Thus, 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid was condensed with neopentylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, Et3N, and 1-hydroxybenzotriazole in DMF at room temperature for 48 h to give 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid N-neopentylamide (II). II showed IC50 of 0.013 μ M for inhibiting the collagen-induced aggregation of human blood platelet.


IT 787563-08-0P, 1-[5-(5-Cyano-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-95-6P
 , 1-[5-(5-Fluoro-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)

RN 787563-08-0 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884596-95-6 CAPLUS

CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-


triazol-3-yl] (4-methoxy-1-piperidinyl)- (CA INDEX NAME)



IT 884597-10-8P, 1-[(5-(5-Aminomethyl-2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4,4-difluoropiperidine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1,5-diheterocycl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)

RN 884597-10-8 CAPLUS

CN Methanone, [5-[5-(aminomethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



IT 884596-93-4P, 1-[(1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4,4-difluoropiperidine
884596-94-5P, 1-[(1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4-methoxypiperidine 884596-96-7P
, 1-[(1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4,4-difluoropiperidine 884596-97-8P,
1-[(1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4-methoxypiperidine 884596-98-9P,
1-[(1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-3,3-difluoroazetidine 884596-99-0P,
1-[(1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4-methylpiperazine 884597-02-8P,
1-[(1-(6-Methoxy-3-pyridyl)-5-(1-methyl-1H-imidazol-4-yl)-1H-1,2,4-triazol-3-yl)carbonyl]-4,4-difluoropiperidine 884597-06-2P,
1-[(1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-4-methyl-3-oxopiperazine 884597-07-3P,
(2S)-1-[(1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl)carbonyl]-2-fluoromethylpyrrolidine 884597-08-4P,


4-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]morpholine 884597-09-5P,
 1-[[5-(5-Carbamoyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884597-11-9P,
 1-[[5-(5-Hydroxymethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,5-diheterocycl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)


RN 884596-93-4 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-94-5 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-96-7 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-97-8 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl) [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-98-9 CAPLUS

CN Methanone, (3,3-difluoro-1-azetidinyl) [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-99-0 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 884597-02-8 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(1-methyl-1H-imidazol-4-yl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884597-06-2 CAPLUS


CN 2-Piperazinone, 4-[(1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl)carbonyl]-1-methyl- (CA INDEX NAME)



RN 884597-07-3 CAPLUS


CN Methanone, [(2S)-2-(fluoromethyl)-1-pyrrolidinyl][1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884597-08-4 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)




RN 884597-09-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884597-11-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[5-[5-(hydroxymethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:497497 CAPLUS Full-text

DOCUMENT NUMBER: 143 : 43882

DOCUMENT NUMBER: 10-10000
TITLE: Preparation

Preparation of 1H-1,2,4-triazole-5-carboxamide derivatives showing CB1-antagonistic activity and combination treatment involving the compounds

INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald;
Krause, Gunter; Lange, Josephus Hubertus Maria; Kruse,
Cornelis Gerrit

PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ. - 27 pp

SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO

DOCUMENT TYPE: CODEN: USAAAC0
Patent

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO

PATENT NO. RE

US 20050124660 A1 20050609 US 2004-969840 20041022
PRIORITY APPLN. INFO.: US 2003-513995P P 20031027
OTHER SOURCE(S): CASREACT 143:43882; MARPAT 143:43882

1



I

AB The present invention relates to a novel medical use of compds. with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivs., 1H-imidazole derivs., thiazole derivs. and/or 1H-1,2,4-triazole-3-carboxamide derivs. or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compds. with


CB1-receptor activity in combination with lipase inhibitors. Said compds. are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclincins, ATL-962 and/or lipstatin. I was prepared and other similar compds. were tested for human cannabinoid CB1 receptor affinity and in vitro antagonism.

IT 676457-12-8P 676457-31-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-1,2,4-triazole-3-carboxamide derivs. showing CB1-antagonistic activity)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:395074 CAPLUS Full-text

DOCUMENT NUMBER: 142:447220

TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands

INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald; Krause, Guenter; Lange, Josephus Hubertus Maria; Kruse, Chris

PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039550	A2	20050506	WO 2004-EP52639	20041022
WO 2005039550	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283056	A1	20050506	AU 2004-283056	20041022
CA 2543338	A1	20050506	CA 2004-2543338	20041022
BR 2004015851	A	20070102	BR 2004-15851	20041022
EP 1753413	A2	20070221	EP 2004-817279	20041022
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
JP 2007513872	T	20070531	JP 2006-536096	20041022
CN 1997364	A	20070711	CN 2004-80030116	20041022
MX 2006004434	A	20060620	MX 2006-4434	20060421
PRIORITY APPLN. INFO.:			EP 2003-103961	A 20031024
			EP 2003-103967	A 20031027
			WO 2004-EP52639	W 20041022

OTHER SOURCE(S):

MARPAT 142:447220

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The novel use of nitrogen heterocycles I-V [R, R1, R5, R11 = Ph, naphthyl, thienyl, pyridyl, etc.; R2, = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl; R7 = (un)branched alkyl] for treatment of cannabinoid-CB1 receptor related diseases, especially in juveniles, is described. A 4-step synthesis of triazolecarboxamide VI.HCl starting from di-Me aminomalonate.HCl 4-chlorobenzoyl chloride, 2,4-dichloroaniline, and 1-aminopiperidine is given. Furthermore, the invention pertains to the use of I-V in combination with lipase inhibitors. Preferred lipase inhibitors are olistat, panclincins, ATL-962, and/or lipstatin.

IT 676457-12-8P 676457-31-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolecarboxamides as cannabinoid-CB1 receptor ligands for treatment of drug-induced obesity in juveniles and adolescents)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:927195 CAPLUS Full-text

DOCUMENT NUMBER: 141:395556

TITLE: Preparation of azole compounds as platelet aggregation inhibitors

INVENTOR(S): Okayama, Toru; Uoto, Kouichi; Ishiyama, Takashi; Kanaya, Naoaki; Kimura, Youichi; Ishihara, Hiroaki; Watanabe, Toshiyuki; Fujii, Kunihiko

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co. Ltd., Japan

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094407	A1	20041104	WO 2004-JP5605	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

OTHER SOURCE(S): MARPAT 141:395556
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. Q-X-Y (I) [Q = II, etc.; Ar1, Ar2 = (un)substituted 6-membered aromatic heterocycles; (un)substituted phenyl; R2 = H, halo, etc.; X = carbonyl, thiocarbonyl; Y = III; A = 4-7 membered ring, further detail on said ring is given; R1 = OH, etc.] were prepared. For example, EDCI-mediated coupling of 2-(6-methoxy-3-pyridyl)-1-(2-pyridyl)-1H-imidazole-4-carboxylic acid with (3R)-fluoropiperidine hydrochloride afforded compound IV in 44% yield. In platelet aggregation inhibition assays, the IC₅₀ value of compound IV was 0.11 μ M. Of note, compds. I inhibit neither COX-1 nor COX-2. Disclosed compds. I are claimed useful for the treatment of ischemia.

IT 787564-53-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azole compds. as platelet aggregation inhibitors for treatment of ischemia)

BN 787564-53-8 CAPIUS

RN 78046-35-0 CASLCS
CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




IT 787562-73-6P 787562-74-7P 787562-75-8P
 787562-76-9P 787562-77-0P 787562-78-1P
 787562-80-5P 787562-81-6P 787562-82-7P
 787562-83-8P 787562-84-9P 787562-85-0P
 787562-86-1P 787562-87-2P 787562-88-3P
 787562-89-4P 787562-90-7P 787562-92-9P
 787563-02-4P 787563-03-5P 787563-07-9P
 787563-08-0P 787563-12-6P 787563-14-8P
 787563-15-9P 787563-16-0P 787563-17-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of azole compds. as platelet aggregation inhibitors for
 treatment of ischemia)

RN 787562-73-6 CAPLUS


CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-74-7 CAPLUS


CN Methanone, [5-(4-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-75-8 CAPLUS

CN Methanone, (4-cyclopropyl-1-piperazinyl)[1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787562-76-9 CAPLUS


CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-phenyl-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-77-0 CAPLUS


CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-78-1 CAPLUS


CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-80-5 CAPLUS

CN Methanone, [3-(dimethylamino)-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787562-81-6 CAPLUS

CN Methanone, [5-(3-fluoro-4-methylphenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-82-7 CAPLUS


CN Methanone, [1-(4-methylphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-83-8 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 787562-84-9 CAPLUS


CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-85-0 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-4,7-diazaspiro[2.5]oct-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




RN 787562-86-1 CAPLUS

CN 2-Piperazinone, 4-[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-87-2 CAPLUS


CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-88-3 CAPLUS

CN 2-Azetidinecarboxamide, 1-[(1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-N,N-dimethyl- (CA INDEX NAME)




RN 787562-89-4 CAPLUS

CN Methanone, [2-[(dimethylamino)methyl]-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 787562-90-7 CAPLUS
 CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(4-methoxyphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787562-92-9 CAPLUS
 CN 2-Piperazinone, 4-[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)




RN 787563-02-4 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 787563-03-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 787563-07-9 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787563-08-0 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)




RN 787563-12-6 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787563-14-8 CAPLUS

CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787563-15-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787563-16-0 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-17-1 CAPLUS
 CN Methanone, [5-(5-chloro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:589415 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:140441
 TITLE: Preparation of imidazole and triazole derivatives useful as selective COX-1 inhibitors
 INVENTOR(S): Takahashi, Fumie; Nakagawa, Toshiya; Matsushima, Yuji; Nakamura, Katsuya
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060367	A1	20040722	WO 2003-JP15921	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003288746 A1 20040729 AU 2003-288746 20031212
 PRIORITY APPLN. INFO.: AU 2002-953602 A 20021230
 AU 2003-901804 A 20030415
 AU 2003-903928 A 20030728
 WO 2003-JP15921 W 20031212

OTHER SOURCE(S): MARPAT 141:140441

GI



AB Imidazole and triazole derivs. were prepared for use as selective COX-1 inhibitors for treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, thrombosis, cancer or neurodegenerative diseases. Thus, 4-PhCH₂OCH₂CH₂C₆H₄NH₂ was treated with 4-MeOC₆H₄CN to give 4-PhCH₂OCH₂CH₂C₆H₄NHC(:NH)C₆H₄OMe-4 which was cyclized with BrCH₂COCF₃ and debenzylated to give the imidazole I. I had IC₅₀ for COX-1 inhibition of < 0.01 and an analgesic coefficient relative to controls of > 1.5.


IT 726197-06-4P 726197-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)


RN 726197-06-4 CAPLUS

CN Methanone, [5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726197-20-2 CAPLUS


CN Methanone, [1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)




IT 726195-26-2P 726195-46-6P 726195-54-6P
 726195-64-8P 726195-74-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)
 RN 726195-26-2 CAPLUS
 CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 726195-46-6 CAPLUS
 CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 726195-54-6 CAPLUS
 CN Urea, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 726195-64-8 CAPLUS

CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 726195-74-0 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:272442 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:303680
 TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands
 INVENTOR(S): Lange, Josephus H. m.; Kruse, Cornelis G.; McCreary, Andrew C.; Van Stuivenberg, Herman H.
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026301	A1	20040401	WO 2003-EP50628	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1402891	A1	20040331	EP 2002-78966	20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20040106614	A1	20040603	US 2003-662477	20030916
US 7319110	B2	20080115		
CA 2491394	A1	20040401	CA 2003-2491394	20030917
AU 2003299024	A1	20040408	AU 2003-299024	20030917
AU 2003299024	B2	20080306		
BR 2003012020	A	20050322	BR 2003-12020	20030917
EP 1542678	A1	20050622	EP 2003-797318	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671377	A	20050921	CN 2003-817352	20030917
CN 1319529	C	20070606		
JP 2006501275	T	20060112	JP 2004-537155	20030917
RU 2325382	C2	20080527	RU 2005-103244	20030917
IN 2004CN03228	A	20060303	IN 2004-CN3228	20041213
ZA 2005000133	A	20051101	ZA 2005-133	20050106
MX 2005002862	A	20050527	MX 2005-2862	20050315
NO 2005001870	A	20050603	NO 2005-1870	20050418
HK 1078796	A1	20071012	HK 2005-110963	20051201
PRIORITY APPLN. INFO.:			EP 2002-78966	A 20020919
			WO 2003-EP50628	W 20030917

OTHER SOURCE(S): MARPAT 140:303680
 GI



AB The title compds. [I; R, R1 = Ph, naphthyl, thienyl, pyridyl, etc.; R2 = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclic] which are potent cannabinoid-CB1 receptor agonists, partial agonists, inverse agonists or antagonists, useful for the treatment of disorders involving cannabinoid neurotransmission, were prepared. E.g., a 4-step synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,4-triazole-3-carboxamide hydrochloride, starting from di-Me aminomalonate.HCl and 4-chlorobenzoyl chloride, was given. The compds. I were tested for in vitro affinity and in vitro antagonism at human cannabinoid-CB1 receptors. The biol. data were given for representative compds. I. The pharmaceutical composition comprising the compound I is claimed.


IT 676457-12-8P 676457-31-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:153570 CAPLUS Full-text
 DOCUMENT NUMBER: 140:391240
 TITLE: Potent imidazole and triazole CB1 receptor antagonists related to SR141716
 AUTHOR(S): Dyck, Brian; Goodfellow, Val S.; Phillips, Teresa; Grey, Jonathan; Haddach, Mustapha; Rowbottom, Martin; Naeve, Gregory S.; Brown, Brock; Saunders, John
 CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1151-1154
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:391240
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clin. candidate, whereas the analogous triazoles are less so due to the absence of an addnl. substituent on the azole ring. Example compds. thus prepared and evaluated were derivs. of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (SR 141716) (I), such as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-1H-1,2,4-triazole-3-carboxamide (II) and 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-methyl-1H-imidazole-4-carboxamide (III).
 IT 683208-86-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of imidazolecarboxamides and triazolecarboxamides related to SR 141716 and study of their activity as cannabinoid CB1 receptor antagonists)
 RN 683208-86-8 CAPLUS

CN Methanone, [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1974:505370 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 81:105370

ORIGINAL REFERENCE NO.: 81:16667a,16670a

TITLE: Heterocyclization of α -acylamino amides. III.

Properties of 5-aminooxazoles

AUTHOR(S): Clerin, Daniel; Fleury, Jean P.

CORPORATE SOURCE: Lab. Chim. Org. Gen., Ec. Super. Chim., Mulhouse, Fr.

SOURCE: Bulletin de la Societe Chimique de France (1974), (1-2, Pt. 2), 211-17

CODEN: BSCFAS; ISSN: 0037-8968

DOCUMENT TYPE: Journal

LANGUAGE: French

GI For diagram(s), see printed CA Issue.

AB Treatment of 5-amino-2-aryl(or alkyl)oxazoles (I; R₂N = piperidino, 1-pyrrolidinyl, morpholino; R₁ = Ph, p-O₂NC₆H₄, p-MeC₆H₄, Me) with electrophiles gave: with H₃O⁺, R₂NCOCH₂NHCOR₁; with (CF₃CO)₂I, 4-CF₃CO derivs. of I; with PhNCO and PhNCS, 4-PhNHCO and 4-PhNCS derivs. of I; with arenediazonium salts, 4-position addition products, some of which rearranged to s-triazoles; and with sulfonyl azides, R₂SO₂N₃ (R = Me, p-MeC₆H₄), cycloaddn. products which rearranged with N elimination, then reacted with a second mol. of I to give II. When I had a Me group in the 4-position, reaction with arenediazonium salts opened the ring.


IT 53423-03-3P 53423-04-4P 53423-19-1P

53423-20-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 53423-03-3 CAPLUS


CN Methanone, (1,5-diphenyl-1H-1,2,4-triazol-3-yl)-4-morpholinyl- (CA INDEX NAME)




RN 53423-04-4 CAPLUS
CN Methanone, [1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 53423-19-1 CAPLUS
CN Methanone, [5-(4-nitrophenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 53423-20-4 CAPLUS
CN Methanone, [1-(4-methylphenyl)-5-(4-nitrophenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1961:131227 CAPLUS Full-text
DOCUMENT NUMBER: 55:131227
ORIGINAL REFERENCE NO.: 55:24729e-i
TITLE: Action of organomagnesium compounds, piperidine, and aromatic thiols on 4-arylazo-2-phenyloxazolin-5-ones
AUTHOR(S): Asker, Wafia; Elagroudi, Zien E.
CORPORATE SOURCE: Cairo Univ., Giza, Egypt
SOURCE: Journal of Organic Chemistry (1961), 26, 1440-3
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 55:131227

GI For diagram(s), see printed CA Issue.


AB The action of excess R'MgX on RNHN:C.N:CPh.O.CO (I) gave 1H-1,2,4-triazoles, RN.CPh:N.C(CR'2OH):N (II). Thus, adding 1 g. I (R = Ph) in 50 ml. C6H6 to PhMgBr (from 0.9 g. Mg and 9 g. PhBr in 50 ml. Et2O), refluxing the mixture 3 hrs., keeping it overnight at 25°, decompg, it with saturated aqueous NH4Cl, extracting with Et2O, evaporating the dried Et2O extract, and triturating the residue with petr. ether gave 60% II (R and R' = Ph), m. 180°. The appropriate I and R'MgBr gave the following II (R, R', % yield, and m.p. given): Ph, p-MeC6H4, 70, 189°, o-MeC6H4, Ph, 60, 152°; p-MeC6H4, Ph, 55, 145°; β-C10H7, Ph, 50, 201°. The products turned red with H2SO4. The action of piperidine on I caused a rearrangement to 1H-1,2,4-triazoles, RN.CPh:N.C(CONC5H10):N (III). Thus, adding 0.5 g. appropriate I to 0.5 ml. distilled. C5H10NH, shaking the mixture 15 min. to a clear solution, keeping it overnight at room temperature, triturating with hot petr. ether, and crystallizing the solids from dilute alc. gave the following III (R, % yield, m.p. given): Ph, 94, 193°; o-MeC6H4, 90, 127°; p-MeC6H4, 82, 141°; β-C10H7, 77, 130°. A similar rearrangement was observed from the action of aromatic thiols on I to also give 1H-1,2,4-triazoles, RN.CPh:N.C(COSR'):N (IV). Thus, heating 1 g. I and 1 g. R'SH at 110 1.5 hrs., cooling, triturating with petr. ether, and crystallizing the residue from EtOH gave the following IV (R, R', % yield, m.p. given): Ph, Ph, 41, 146°; Ph, p-MeC6H4, 62, 195°; o-MeC6H4, p-MeC6H4, - 55, 181; p-MeC6H4, p-MeC6H4, 41, 177°; β-C10H7, p-MeC6H4, 46, 183°.

IT 111384-11-3P, Piperidine, 1-(1,5-diphenyl-1H-1,2,4-triazol-3-ylcarbonyl)- 115101-88-7P, Piperidine, 1-[5-phenyl-1-p-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- 115163-48-9P, Piperidine, 1-[5-phenyl-1-o-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- 122680-09-5P, Piperidine, 1-[1-(2-naphthyl)-5-phenyl-1H-1,2,4-triazol-3-ylcarbonyl]-

RL: PREP (Preparation)
(preparation of)


RN 111384-11-3 CAPLUS

CN Methanone, (1,5-diphenyl-1H-1,2,4-triazol-3-yl)-1-piperidinyl- (CA INDEX NAME)




RN 115101-88-7 CAPLUS


CN Methanone, [1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 115163-48-9 CAPLUS
CN Methanone, [1-(2-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 122680-09-5 CAPLUS
CN Methanone, [1-(2-naphthalenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 11:31:24 ON 30 MAR 2009